|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococ- cus aureus显示文摘 | Stryjewski ME Chambers HF | 2008 | Clin Infect Dis2008，46，5： | 1 |
| 2 | Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians,African-Americans,and West Africans显示文摘 | Velez DR Wejse C Stryjewski ME | 2010 | Hum Genet2010，127，1： | 1 |
| 3 | Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive or- ganisms显示文摘 | Stryjewski ME Graham DR Wilson SE | 2008 | Clin lnfect Dis2008，46，11： | 1 |
| 4 | NOS2A, TLR4, and IFN- GR1 interactions influence pulmonary tuberculosis susceptibili- ty in African-Americans显示文摘 | Velez DR Hulme WF Myers JL Weinberg JB Levesque MC Stryjewski ME Abbate E Estevan R Patillo SG Gil- bert JR Hamilton CD Scott WK | 2009 | Hum Genet2009，126，5： | 1 |
| 5 | Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus显示文摘 | Stryjewski ME Chambers HF | | 0，，： | 1 |
| 6 | Telavancin for thetreatment of serious gram-positive infections, including hospital ac-quired pneumonia 显示文摘 | Rubinstein E Corey GR Stryjewski ME | 2011 | Expert opinion on pharmacotherapy2011，12，17： | 1 |
| 7 | Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections 显示文摘 | Stryjewski ME Barriere SL ORiordan W | 2012 | J Antimicrob Chemother2012，67，6： | 1 |
| 8 | Association of SLCI IAI with tuberculosis and interactions with NOS2A and TLR2 in African-Americans and Caucasians显示文摘 | Velez DR Hulme WF Myers JL Stryjewski ME Abbate E Esreran R | 2009 | lnt J Tuberc Lung Dis2009，13，9： | 1 |
| 9 | ATLAS 1: the first Phase 3 study evaluating the new lipoglycopeptide, telavancin, for the treatment of patients with complicated skin and skin structure infections 显示文摘 | COREY GR STRYJEWSKI ME O'RIORDAN WD | 2007 | Clin Microb Infect2007，292，： | 1 |
| 10 | ATLAS 2: a double-blind, randomised, active controlled, multinational Phase 3 study comparing telavancin with vancomycin for the treatment of patients with complicated skin and skin structure infections显示文摘 | COREY GR STRYJEWSKI ME FOWLER VG | 2007 | Clin Microb Infect2007，292，： | 1 |
| 11 | Gram-negative bloodstreaminfections显示文摘 | Stryjewski ME Boucherc HW | 2009 | Int J Ant-Imicrob Agents2009，34，4： | 1 |
| 12 | A new lipoglycopeptide: telavanein 显示文摘 | Nannini EC Stryjewski ME | 2008 | Expert Opin Pharmacother2008，9，： | 1 |
| 13 | Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram -positive bacteria:FAST 2 study显示文摘 | Stryjewski ME Chu VH O Riordan WD | 2006 | Antimicrob Agents Chemother2006，50，： | 1 |
| 14 | Telavancin versus vancomycin for the treatment of complicated skin and skin - structure infections caused by gram - positive organisms 显示文摘 | Stryjewski ME Graham DR Wilson SE | 2008 | Clin Infect Dis2008，46，： | 1 |
| 15 | Expression of antimicrobial peptides in the normal and involved skin of patients with infective cellulitis显示文摘 | Stryjewski ME Hall RP Chu VH | 2007 | J Infect Dis2007，196，： | 1 |
| 16 | Telavancin versus standard therapy for treatment of complicated skin and skin structure infections due to gram positive bacteria显示文摘 | Stryjewski ME O' Riordan WD Lau WK | 2005 | Clin Infect Dis2005，40，： | 1 |
| 17 | Skin and Soft-Tissue Infections Caused by Community-Acquired Methieillin-ResistantStaphylocoe- cus aureus 显示文摘 | Stryjewski ME Chambers HF | 2008 | Clinical Infectious Diseases2008，46，： | 1 |
| 18 | Telavancin 显示文摘 | Corey GR Stryjewski ME Weyenberg W | 2009 | Nat Rev Drug Dis2009，8，12： | 1 |
| 19 | Variants in toll-like receptors 2 and 9 influence susceptibility to pul- monary tuberculosis in Caucasians, African-Americans, and West Africans显示文摘 | Velez DR Wejse C Stryjewski ME | 2010 | Hum Genet2010，127，1： | 1 |
| 20 | Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival显示文摘 | Stryjewski ME Hopkins A Barriere SL | 2014 | Antimicrob Agents Chemother2014，58，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员